Details of the Drug-Related molecule(s) Interaction Atlas

BRN-1980310 Drug Info

Benzo(a)pyrene, 9-hydroxy-; 9-Hydroxybenzo(a)Pyrene; Benzo[def]chrysen-9-ol; LS-40103; SCHEMBL3348130; ZINC4655178; benzo[a]pyren-9-ol; 17573-21-6; 9-Hydroxy Benzopyrene; 9-Hydroxy benzo[a]pyrene; 9-Hydroxybenzo[a]pyrene; 9-hydroxybenzo(a)pyrene, 3H-labeled; AC1L1FO7; ACM17573216; AKOS027321432; BIDD:ER0395; BRN 1980310; CCRIS 1073; CHEBI:34512; BENZO(a)PYREN-9-OL; CHEMBL351406; CTK0H8447; DTXSID20170012; FT-0669411

Cross-matching ID

PubChem CID

28598

ChEBI ID

CHEBI:34512

CAS Number

CAS 17573-21-6

TTD Drug ID

DMOTU4P

INTEDE Drug ID

DR1966

General Information of Drug (ID: DMOTU4P)

Molecule-Related Drug Atlas

Molecule Type:

DME

Drug Status:

Approved Drug(s)

Investigative Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Metabolized By UDP-glucuronosyltransferase 2B15 (UGT2B15)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[2]
Ezetimibe	DM7A8TW	Atherosclerosis	BD40	Approved	[3]
Lorazepam	DM84ZXF	Absence epilepsy		Approved	[4]
Hydroxybenzo[a]pyrene	DMFSKYE	N. A.	N. A.	Investigative	[1]
Hydroxybenzo(a)pyrene	DM9H5EN	N. A.	N. A.	Investigative	[1]
------------------------------------------------------------------------------------

Drug(s) Metabolized By UDP-glucuronosyltransferase 2B17 (UGT2B17)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[5]
Darolutamide	DMV7YFT	Prostate cancer	2C82.0	Approved	[6]
Denopamine	DM8C3GN	Cardiac disease	BA00-BE2Z	Approved	[7]
MK-7246	DMLQOF1	Respiratory disease	CB40	Phase 1	[8]
Hydroxybenzo[a]pyrene	DMFSKYE	N. A.	N. A.	Investigative	[1]
Hydroxybenzo(a)pyrene	DM9H5EN	N. A.	N. A.	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
UDP-glucuronosyltransferase 2B15 (UGT2B15)	DENZ6B1	UDB15_HUMAN	Substrate	[1]
UDP-glucuronosyltransferase 2B17 (UGT2B17)	DEAZDL8	UDB17_HUMAN	Substrate	[1]

------------------------------------------------------------------------------------

References

1	Importance of UDP-glucuronosyltransferase 1A10 (UGT1A10) in the detoxification of polycyclic aromatic hydrocarbons: decreased glucuronidative activity of the UGT1A10139Lys isoform. Drug Metab Dispos. 2006 Jun;34(6):943-9.
2	Characterization of niflumic acid as a selective inhibitor of human liver microsomal UDP-glucuronosyltransferase 1A9: application to the reaction phenotyping of acetaminophen glucuronidation. Drug Metab Dispos. 2011 Apr;39(4):644-52.
3	Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
4	Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers. Clin Pharmacol Ther. 2005 Jun;77(6):486-94.
5	Age-dependent hepatic UDP-glucuronosyltransferase gene expression and activity in children. Front Pharmacol. 2016 Nov 16;7:437.
6	Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):747-759.
7	Regioselective glucuronidation of denopamine: marked species differences and identification of human udp-glucuronosyltransferase isoform. Drug Metab Dispos. 2005 Mar;33(3):403-12.
8	UGT2B17 genetic polymorphisms dramatically affect the pharmacokinetics of MK-7246 in healthy subjects in a first-in-human study. Clin Pharmacol Ther. 2012 Jul;92(1):96-102.